Abstract
Antitumor immune response requires the presence, activation, and stimulation of all lymphoid components of the immune system. An increasing number of studies on this topic have led to the recognizing that the accumulation of tumor-infiltrating lymphocytes (TILs) in gynecological cancer is prognostic for increased survival through activation of an advanced immune response.
Cancer immunoediting, the interaction process between the immune system and tumor, represents a dynamic process, with TILs playing an important role in antitumor response. Cancer development may be constrained or promoted by the immune system in three specific steps: elimination, equilibrium, and escape.
Recently, therapies that modulate the immune system have emerged as a new, effective, life-changing approach in several cancers. Combination of immunotherapy and traditional treatments has proved effective in preventing tumor development, thus improving both the prognosis and overall survival of cancer patients. Immunomodulatory therapies have already become standard of care for some cancers. Such an approach can possibly be extended also to gynecological cancers. Despite extensive knowledge in tumor diagnosis and treatment, new strategies are strongly required that while effective at attacking the disease, can also be more tolerable.
This chapter is devoted to authors’ analysis of tumor response mechanisms and TILs action in gynecological malignancies, both from a molecular and a clinical perspective.
This is a preview of subscription content, log in via an institution to check access.
References
Bekos C, Pils D, Dekan S et al (2021) PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome. Sci Rep 11(1):6400. https://doi.org/10.1038/s41598-021-85966-0
Berghoff AS, Fuchs E, Ricken G, Mlecnik B, Bindea G, Spanberger T et al (2016) Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. Onco Targets Ther 5:5. https://doi.org/10.1080/2162402X.2015.1057388
Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15:10–17. https://doi.org/10.1016/0090-8258(83)90111-7
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [published correction appears in CA Cancer J Clin. 2020 Jul;70(4):313]. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492
Brewer MA, Johnson K, Follen M, Gershenson D, Bast R Jr (2003) Prevention of ovarian cancer: intraepithelial neoplasia. Clin Cancer Res 9(1):20–30
Chen R, Gong Y, Zou D, Wang L, Yuan L, Zhou Q (2019) Correlation between subsets of tumor-infiltrating immune cells and risk stratification in patients with cervical cancer. PeerJ 2019:e7804. https://doi.org/10.7717/PEERJ.7804/SUPP-1
Clarke B, Tinker AV, Lee C-H, Subramanian S, van de Rijn M, Turbin D et al (2008) Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol 22:393–402. https://doi.org/10.1038/modpathol.2008.191
Colombo N, Sessa C, du Bois A et al (2019) ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. Ann Oncol 30(5):672–705. https://doi.org/10.1093/annonc/mdz062
Concin N, Matias-Guiu X, Vergote I et al (2021) ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 31(1):12–39. https://doi.org/10.1136/ijgc-2020-002230
Crum CP, Drapkin R, Kindelberger D, Medeiros F, Miron A, Lee Y (2007) Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res 5(1):35–44. https://doi.org/10.3121/cmr.2007.702
D’Alessandris N, Palaia I, Pernazza A, Tomao F, di Pinto A, Musacchio L et al (2020) PD-L1 expression is associated with tumor infiltrating lymphocytes that predict response to NACT in squamous cell cervical cancer. Virchows Arch 478:517–525. https://doi.org/10.1007/S00428-020-02922-5
de Jong RA, Leffers N, Boezen HM, Ten Hoor KA, van der Zee AG, Hollema H, Nijman HW (2009) Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. Gynecol Oncol 114:105–110. https://doi.org/10.1016/J.YGYNO.2009.03.022
Ding M, Mei-jiao G (1991) Immune effect of tumor-infiltrating lymphocytes and its relation to the survival rate of patients with ovarian malignancies. J Tongji Med Univ 11:235–239. https://doi.org/10.1007/BF02888158
Dötzer K, Schlüter F, Schoenberg MB et al (2019) Immune heterogeneity between primary tumors and corresponding metastatic lesions and response to platinum therapy in primary ovarian cancer. Cancers (Basel) 11(9):1250. https://doi.org/10.3390/cancers11091250
Enwere EK, Kornaga EN, Dean M, Koulis TA, Phan T, Kalantarian M et al (2017) Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer. Mod Pathol 30:577–586. https://doi.org/10.1038/modpathol.2016.221
Fontham ETH, Wolf AMD, Church TR, Etzioni R, Flowers CR, Herzig A et al (2020) Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin 70:321–346. https://doi.org/10.3322/CAAC.21628
Gatta G, Capocaccia R, Trama A, Martínez-García C, RARECARE Working Group (2010) The burden of rare cancers in Europe. Adv Exp Med Biol 686:285–303. https://doi.org/10.1007/978-90-481-9485-8_17
Giatromanolaki A, Kouroupi M, Kontomanolis EN, Koukourakis MI (2021) Regulatory tumor-infiltrating lymphocytes prevail in endometrial tumors with low vascular survival ability. Immunobiology 226(3):152078. https://doi.org/10.1016/j.imbio.2021.152078
Gill CM, D’Andrea MR, Tomita S, Suhner J, Umphlett M, Zakashansky K et al (2021) Tumor immune microenvironment in brain metastases from gynecologic malignancies. Cancer Immunol Immunother 70:2951–2960. https://doi.org/10.1007/S00262-021-02909-4
Ginsburg O, Bray F, Coleman MP et al (2017) The global burden of women’s cancers: a grand challenge in global health. Lancet 389(10071):847–860. https://doi.org/10.1016/S0140-6736(16)31392-7
Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM (2007) Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet (Lond, Engl) 370:59–67. https://doi.org/10.1016/S0140-6736(07)61050-2
Guido R (2018) Cervical cancer screening. Clin Obstet Gynecol 61:40–51. https://doi.org/10.1097/GRF.0000000000000336
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. https://doi.org/10.1016/j.cell.2011.02.013
Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S et al (2015) Association of polymerase e–mutated and microsatellite-instable endometrial cancers with Neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol 1:1319–1323. https://doi.org/10.1001/JAMAONCOL.2015.2151
Hunn J, Rodriguez GC (2012) Ovarian cancer: etiology, risk factors, and epidemiology. Clin Obstet Gynecol 55(1):3–23. https://doi.org/10.1097/GRF.0b013e31824b4611
Hwang W-T, Adams SF, Tahirovic E, Hagemann IS, Coukos G (2012) Prognostic significance of tumor-infiltrating T-cells in ovarian cancer: a meta-analysis. Gynecol Oncol 124:192. https://doi.org/10.1016/J.YGYNO.2011.09.039
Jayson GC, Kohn EC, Kitchener HC, Ledermann JA (2014) Ovarian cancer. Lancet 384:1376–1388. https://doi.org/10.1016/S0140-6736(13)62146-7
Jiang Y, Wang C, Zhou S (2020) Targeting tumor microenvironment in ovarian cancer: premise and promise. Biochim Biophys Acta Rev Cancer 1873:188361. https://doi.org/10.1016/J.BBCAN.2020.188361
Johnson CA, James D, Marzan A, Armaos M (2019) Cervical cancer: an overview of pathophysiology and management. Semin Oncol Nurs 35:166–174. https://doi.org/10.1016/J.SONCN.2019.02.003
Khoja L, Butler MO, Kang SP, Ebbinghaus S, Joshua AM (2015) Pembrolizumab. J Immunother Cancer 3:36. https://doi.org/10.1186/S40425-015-0078-9
Kim KH, Choi KU, Kim A et al (2019) PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma [published correction appears in J ovarian res. 2019 Jul 23;12(1):68]. J Ovarian Res 12(1):56. https://doi.org/10.1186/s13048-019-0526-0
Kuchenbaecker KB, Hopper JL, Barnes DR et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402–2416. https://doi.org/10.1001/jama.2017.7112
Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, Wang TL et al (2009) Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 174:1597. https://doi.org/10.2353/AJPATH.2009.081000
Kurman RJ, Shih IM (2016) The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol 186:733. https://doi.org/10.1016/J.AJPATH.2015.11.011
Lastwika KJ, Wilson W, Li QK, Norris J, Xu H, Ghazarian SR et al (2016) Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer. Cancer Res 76:227–238. https://doi.org/10.1158/0008-5472.CAN-14-3362
Lee WS, Yang H, Chon HJ, Kim C (2020) Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp Mol Med 52(9):1475–1485. https://doi.org/10.1038/s12276-020-00500-y
Leffers N, Gooden MJM, de Jong RA, Hoogeboom B-N, ten Hoor KA, Hollema H et al (2008) Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother 58:449–459. https://doi.org/10.1007/S00262-008-0583-5
Liang Y, Lü W, Zhang X, Lü B (2018) Tumor-infiltrating CD8+ and FOXP3+ lymphocytes before and after neoadjuvant chemotherapy in cervical cancer. Diagn Pathol 13:13. https://doi.org/10.1186/S13000-018-0770-4
Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR (2009) Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet 76(1):1–18. https://doi.org/10.1111/j.1399-0004.2009.01230.x
Marth C, Landoni F, Mahner S et al (2018) Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(Suppl 4):iv262. https://doi.org/10.1093/annonc/mdy160
Medeiros F, Muto MG, Lee Y et al (2006) The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 30(2):230–236. https://doi.org/10.1097/01.pas.0000180854.28831.77
Menon U, Gentry-Maharaj A, Burnell M, Singh N, Ryan A, Karpinskyj C et al (2021) Ovarian cancer population screening and mortality after long-term follow-up in the UK collaborative trial of ovarian cancer screening (UKCTOCS): a randomised controlled trial. Lancet (Lond, Engl) 397:2182. https://doi.org/10.1016/S0140-6736(21)00731-5
Mittica G, Capellero S, Genta S, Cagnazzo C, Aglietta M, Sangiolo D et al (2016) Adoptive immunotherapy against ovarian cancer. J Ovarian Res 9:9. https://doi.org/10.1186/S13048-016-0236-9
Murali R, Soslow RA, Weigelt B (2014) Classification of endometrial carcinoma: more than two types. Lancet Oncol 15(7):e268–e278. https://doi.org/10.1016/S1470-2045(13)70591-6
Nielsen JS, Nelson BH (2012) Tumor-infiltrating B cells and T cells. Onco Targets Ther 1:1623–1625. https://doi.org/10.4161/ONCI.21650
Oda K, Hamanishi J, Matsuo K, Hasegawa K (2018) Genomics to immunotherapy of ovarian clear cell carcinoma: unique opportunities for management. Gynecol Oncol 151:381–389. https://doi.org/10.1016/J.YGYNO.2018.09.001
Peng J, Hamanishi J, Matsumura N, Abiko K, Murat K, Baba T et al (2015) Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-κBto foster an immunosuppressive tumor microenvironment in ovarian cancer. Cancer Res 75:5034–5045
Redjimi N, Raffin C, Raimbaud I, Pignon P, Matsuzaki J, Odunsi K et al (2012) CXCR3+ T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity. Cancer Res 72:4351–4360. https://doi.org/10.1158/0008-5472.CAN-12-0579
Risch HA (1998) Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 90(23):1774–1786. https://doi.org/10.1093/jnci/90.23.1774
Rodriguez GC, Nagarsheth NP, Lee KL et al (2002) Progestin-induced apoptosis in the macaque ovarian epithelium: differential regulation of transforming growth factor-beta. J Natl Cancer Inst 94(1):50–60. https://doi.org/10.1093/jnci/94.1.50
Ryan NAJ, Morris J, Green K et al (2017) Association of mismatch repair mutation with age at cancer onset in lynch syndrome: implications for stratified surveillance strategies. JAMA Oncol 3(12):1702–1706. https://doi.org/10.1001/jamaoncol.2017.0619
Salazar C, Campbell IG, Gorringe KL (2018) When is “type I” ovarian cancer not “type I”? Indications of an out-dated dichotomy. Front Oncol 8:654. https://doi.org/10.3389/FONC.2018.00654/BIBTEX
Sankaranarayanan R, Ferlay J (2006) Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol 20(2):207–225. https://doi.org/10.1016/j.bpobgyn.2005.10.007
Santoiemma PP, Powell DJ Jr (2015) Tumor infiltrating lymphocytes in ovarian cancer. Cancer Biol Ther 16:807. https://doi.org/10.1080/15384047.2015.1040960
Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F et al (2005) Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 102:18538. https://doi.org/10.1073/PNAS.0509182102
Schwab CL, English DP, Roque DM, Pasternak M, Santin AD (2014) Past, present and future targets for immunotherapy in ovarian cancer. Immunotherapy 6:1279. https://doi.org/10.2217/IMT.14.90
Seton-Rogers S (2018) Oncogenes: driving immune evasion. Nat Rev Cancer 18:67. https://doi.org/10.1038/NRC.2018.5
Shan W, Liu J (2009) Inflammation: a hidden path to breaking the spell of ovarian cancer. Cell Cycle 8(19):3107–3111. https://doi.org/10.4161/cc.8.19.9590
Shin HY, Lee B, Hwang S-H, Lee DO, Sung NY, Park JY et al (2019) Evaluation of satisfaction with three different cervical cancer screening modalities: clinician-collected pap test vs. HPV test by self-sampling vs. HPV test by urine sampling. J Gynecol Oncol 30:1–10. https://doi.org/10.3802/JGO.2019.30.E76
Soslow RA, Han G, Park KJ, Garg K, Olvera N, Spriggs DR et al (2011) Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. Mod Pathol 25:625–636. https://doi.org/10.1038/modpathol.2011.183
Stewart C, Ralyea C, Lockwood S (2019) Ovarian cancer: an integrated review. Semin Oncol Nurs 35:151–156. https://doi.org/10.1016/J.SONCN.2019.02.001
Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660
Tomšová M, Melichar B, Sedláková I, Šteiner I (2008) Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol 108:415–420. https://doi.org/10.1016/J.YGYNO.2007.10.016
van Gool IC, Eggink FA, Freeman-Mills L, Stelloo E, Marchi E, de Bruyn M et al (2015) POLE proofreading mutations elicit an antitumor immune response in endometrial cancer. Clin Cancer Res 21:3347–3355
Ventriglia J, Paciolla I, Pisano C, Cecere SC, di Napoli M, Tambaro R et al (2017) Immunotherapy in ovarian, endometrial and cervical cancer: state of the art and future perspectives. Cancer Treat Rev 59:109–116. https://doi.org/10.1016/J.CTRV.2017.07.008
Yaguchi T, Kawakami Y (2016) Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation. Int Immunol 28:393–399. https://doi.org/10.1093/INTIMM/DXW030
Yap TA, Plummer R, Azad NS, Helleday T (2019) The DNA damaging revolution: PARP inhibitors and beyond. Am Soc Clin Oncol Educ Book 39:185–195. https://doi.org/10.1200/EDBK_238473
Zhan L, Liu X, Zhang J, Cao Y, Wei B (2020) Immune disorder in endometrial cancer: immunosuppressive microenvironment, mechanisms of immune evasion and immunotherapy. Oncol Lett 20:2075. https://doi.org/10.3892/OL.2020.11774
Zhang T, Liu Q, Zhu Y, Huang Y, Qin J, Wu X et al (2021) Lymphocyte and macrophage infiltration in omental metastases indicates poor prognosis in advance stage epithelial ovarian cancer. J Int Med Res 49:49. https://doi.org/10.1177/03000605211066245
Acknowledgments
We thank Dr. Daniela Masi (AUSL-IRCCS di Reggio Emilia) for English editing.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The authors declare that there is no conflict of interest.
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Melli, B., Sileo, F.G., Palicelli, A., Kuhn, E., Nardi, V., Mandato, V.D. (2023). Tumor-Infiltrating Lymphocytes (TILs) and Gynecological Cancers. In: Interdisciplinary Cancer Research. Springer, Cham. https://doi.org/10.1007/16833_2023_161
Download citation
DOI: https://doi.org/10.1007/16833_2023_161
Published:
Publisher Name: Springer, Cham